Macau Casino Gambli...
Health Care: Drugs
Alnylam Pharmaceuticals Inc. (ALNY: NASDAQ)
$10.09 -0.15 | -1.46%
06/01/12 - 04:00 PM ET
Company Income Statement
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Sales | 82.76M | 100.04M | 100.53M | 96.16M |
| Cost of Sales | -5.12M | -4.94M | -5.99M | -5.73M |
| Gross Operating Profit | 87.88M | 104.98M | 106.52M | 101.89M |
| Selling, General, and Administrative Expenses | 38.28M | 37.73M | 39.91M | 27.12M |
| Research & Development | 99.30M | 106.38M | 108.73M | 96.88M |
| Operating Income before D & A (EBITDA) | -49.69M | -39.13M | -42.12M | -22.11M |
| Depreciation & Amortization | 5.12M | 4.94M | 5.99M | 5.73M |
| Interest Income | 1.20M | 2.30M | 5.38M | 14.41M |
| Other Income - Net | -531.00K | 6.40M | 628.00K | -1.95M |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -57.65M | -43.00M | -47.01M | -24.66M |
| Interest Expense | 0.00 | 0.00 | 0.00 | 872.00K |
| Pre-Tax Income | -57.65M | -43.00M | -47.01M | -25.53M |
| Income Taxes | 0.00 | 514.00K | 582.00K | 719.00K |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -57.65M | -43.52M | -47.59M | -26.25M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -57.65M | -43.52M | -47.59M | -26.25M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -57.65M | -43.52M | -47.59M | -26.25M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-57.65M | -43.52M | -47.59M | -26.25M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -57.65M | -43.52M | -47.59M | -26.25M |
| Basic EPS from Continuing Ops. | -1.36 | -1.04 | -1.14 | -0.64 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -1.36 | -1.04 | -1.14 | -0.64 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -1.36 | -1.04 | -1.14 | -0.64 |
| Basic Normalized Net Income/Share | -1.36 | -1.04 | -1.14 | -0.64 |
| EPS fr Continuing Ops. | -1.36 | -1.04 | -1.14 | -0.64 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -1.36 | -1.04 | -1.14 | -0.64 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -1.36 | -1.04 | -1.14 | -0.64 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-1.36 | -1.04 | -1.14 | -0.64 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with ALNY
- Portfolio NameUser Type
- UserThe #1 Growth Fund To Make ...
- ContributorStocks With Big Insider Buy...
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- Userkite
- UserPART 6 JPMorgan 28th Annual...
- UserWilliam T Blanchard - Medical
- ContributorHealthcare Short Squeezes f...
- UserS.A.Chili
- UserHancock Hallock Firm
Latest ALNY Headlines from TheStreet
- 5 Stocks Insiders Love Right Now 02.24.12 | 12:02 pm
- 8 Stocks Rising on Huge Volume 02.15.12 | 02:02 pm
- 'Mad Money Lightning Round': Stay Long Sandridge 01.03.12 | 07:01 pm
- Cramer's 'Mad Money' Recap: Betting Against the Bears (Update 2) 01.03.12 | 06:01 pm
- AK Steel, Applied Materials: New Ratings 02.23.11 | 09:02 am
- Layoffs Mount in 2010: What Does It Mean for 2011? 01.06.11 | 05:01 pm
- Alnylam Pharmaceuticals CEO Discusses Q3 2010 Results  Earnings Call Transcript 11.03.10 | 10:11 pm
- Biotech Stock Mailbag: Cyclacel Pharma 10.08.10 | 07:10 am
- Alnylam Cuts Jobs On Partner Exit 09.24.10 | 07:09 am
- Alnylam Pharmaceuticals, Inc. Q2 2010 Earnings Call Transcript 08.05.10 | 12:08 am
Press Releases for ALNY
- Alnylam Announces Top-Line Results Of Phase IIb Clinical Trial Of ALN-RSV01, An Inhaled RNAi Therapeutic For The Treatment Of Respiratory Syncytial Virus (RSV) Infection - Business Wire 05.30.12 | 06:05 am
- Alnylam And PBL Sign License Agreement For Baulcombe & Hamilton RNAi Patent - Business Wire 05.23.12 | 08:05 am
- Alnylam Pharmaceuticals Reports First Quarter 2012 Financial Results - Business Wire 05.03.12 | 04:05 pm
- Alnylam To Webcast Conference Call Discussing First Quarter 2012 Financial Results - Business Wire 04.26.12 | 04:04 pm
- Alnylam To Webcast Presentation At Future Leaders In The Biotech Industry Conference - Business Wire 04.13.12 | 04:04 pm
- Alnylam To Webcast Presentation At 11th Annual Needham Healthcare Conference - Business Wire 03.27.12 | 04:03 pm
- Alnylam Initiates Phase I Clinical Study Of ALN-TTR02, An RNAi Therapeutic Targeting Transthyretin (TTR) For The Treatment Of TTR-Mediated Amyloidosis (ATTR) - Business Wire 03.19.12 | 08:03 am
- Alnylam Retains Key Claims For Kinesin Spindle Protein (KSP) RNAi Patent In Interference Proceedings - Business Wire 03.14.12 | 06:03 am
- Alnylam To Webcast Presentation At Barclays Capital Global Healthcare Conference - Business Wire 03.06.12 | 04:03 pm
- Alnylam And The University Of Massachusetts Medical School Announce Tuschl I Patent Upheld In European Opposition Proceedings - Business Wire 03.01.12 | 11:03 am
Partner Headlines for ALNY
- The Zacks Analyst Blog Highlights: Amgen, Sanofi, Regeneron, Alnylam and Coach - Press Releases - Zacks 03.28.12 | 09:03 am
- What Alnylam Doesn't Want You To Know - Seeking Alpha 03.16.12 | 09:03 am
- Tekmira: RNAi Company With Long Term Potential, Short Term Catalysts - Seeking Alpha 03.07.12 | 08:03 am
- Company News for February 15, 2012 - Corporate Summary - Zacks 02.15.12 | 10:02 am
- Alnylam Pharma Up 8% After Pricing Public Offering - Benzinga 02.15.12 | 09:02 am
- Alnylam Delivers In-Line Numbers - Analyst Blog - Zacks 02.13.12 | 10:02 am
- Verastem IPO Validates Investor Interest In Cancer Stem Cell Approach - Seeking Alpha 01.30.12 | 09:01 am
- Alnylam Down to Neutral - Analyst Blog - Zacks 01.20.12 | 04:01 pm
- 16 Healthcare Stocks Deeply Discounted From Target Price - Seeking Alpha 01.12.12 | 09:01 am
- Alnylam States Preclinical Data - Analyst Blog - Zacks 12.30.11 | 04:12 pm
